In a January investor update, Immutep confirmed that all clinical programs are progressing as expected with final or interim readouts from all studies to come in 2019E. The key catalyst is Phase IIb data from the AIPAC trial for lead asset eftilagimod alpha ("efti") in combination with chemotherapy (paclitaxel) in metastatic breast cancer ("mBC"), for which data is expected in H2/2019E. Efti accounts for >90% of our sum of the parts derived target price ("TP") of A$0.078 per share, with the mBC ....
05 Feb 2019
2019 a decisive year rich in news flow
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2019 a decisive year rich in news flow
In a January investor update, Immutep confirmed that all clinical programs are progressing as expected with final or interim readouts from all studies to come in 2019E. The key catalyst is Phase IIb data from the AIPAC trial for lead asset eftilagimod alpha ("efti") in combination with chemotherapy (paclitaxel) in metastatic breast cancer ("mBC"), for which data is expected in H2/2019E. Efti accounts for >90% of our sum of the parts derived target price ("TP") of A$0.078 per share, with the mBC ....